S-5751

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530137

CAS#: 209268-36-0

Description: S-5751 is a prostanoid DP (DP1) antagonist potentially for the treatment of bronchial asthma.


Chemical Structure

img
S-5751
CAS# 209268-36-0

Theoretical Analysis

MedKoo Cat#: 530137
Name: S-5751
CAS#: 209268-36-0
Chemical Formula: C25H31NO4S
Exact Mass: 441.2
Molecular Weight: 441.59
Elemental Analysis: C, 68.00; H, 7.08; N, 3.17; O, 14.49; S, 7.26

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: S-5751; S5751; S 5751

IUPAC/Chemical Name: (5Z)-7-((1R,2R,3S,5S)-2-(((5-Hydroxy-1-benzothien-3-yl)carbonyl)amino)-6,6-dimethylbicyclo(3.1.1)hept-3-yl)hept-5-enoic acid

InChi Key: ZXBHFWFKSIYJEK-MFJOXFORSA-N

InChi Code: InChI=1S/C25H31NO4S/c1-25(2)16-11-15(7-5-3-4-6-8-22(28)29)23(20(25)12-16)26-24(30)19-14-31-21-10-9-17(27)13-18(19)21/h3,5,9-10,13-16,20,23,27H,4,6-8,11-12H2,1-2H3,(H,26,30)(H,28,29)/b5-3-/t15-,16-,20-,23+/m0/s1

SMILES Code: O=C(O)CCC/C=C\C[C@@H]1[C@@H](NC(C2=CSC3=CC=C(O)C=C23)=O)[C@@](C4)([H])C(C)(C)[C@@]4([H])C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 441.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Arimura A, Yasui K, Kishino J, Asanuma F, Hasegawa H, Kakudo S, Ohtani M,
Arita H. Prevention of allergic inflammation by a novel prostaglandin receptor
antagonist, S-5751. J Pharmacol Exp Ther. 2001 Aug;298(2):411-9. PubMed PMID:
11454901.

2: Shichijo M, Arimura A, Hirano Y, Yasui K, Suzuki N, Deguchi M, Abraham WM. A
prostaglandin D2 receptor antagonist modifies experimental asthma in sheep. Clin
Exp Allergy. 2009 Sep;39(9):1404-14. doi: 10.1111/j.1365-2222.2009.03275.x.
PubMed PMID: 19486034.

3: Hirano Y, Shichijo M, Ikeda M, Kitaura M, Tsuchida J, Asanuma F, Yanagimoto T,
Furue Y, Imura K, Yasui K, Arimura A. Prostanoid DP receptor antagonists suppress
symptomatic asthma-like manifestation by distinct actions from a glucocorticoid
in rats. Eur J Pharmacol. 2011 Sep;666(1-3):233-41. doi:
10.1016/j.ejphar.2011.05.003. PubMed PMID: 21596028.

4: Yasui K, Asanuma F, Hirano Y, Shichijo M, Deguchi M, Arimura A. Contribution
of prostaglandin D2 via prostanoid DP receptor to nasal hyperresponsiveness in
guinea pigs repeatedly exposed to antigen. Eur J Pharmacol. 2008 Jan
14;578(2-3):286-91. PubMed PMID: 17927976.

5: Mitsumori S, Tsuri T, Honma T, Hiramatsu Y, Okada T, Hashizume H, Kida S,
Inagaki M, Arimura A, Yasui K, Asanuma F, Kishino J, Ohtani M. Synthesis and
biological activity of various derivatives of a novel class of potent, selective,
and orally active prostaglandin D2 receptor antagonists. 2.
6,6-Dimethylbicyclo[3.1.1]heptane derivatives. J Med Chem. 2003 Jun
5;46(12):2446-55. PubMed PMID: 12773048.

6: Takahashi G, Asanuma F, Suzuki N, Hattori M, Sakamoto S, Kugimiya A, Tomita Y,
Kuwajima G, Abraham WM, Deguchi M, Arimura A, Shichijo M. Effect of the potent
and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of
allergic rhinitis and allergic asthma. Eur J Pharmacol. 2015 Oct 15;765:15-23.
doi: 10.1016/j.ejphar.2015.08.003. PubMed PMID: 26277322.

7: Choi YH, Lee SN, Aoyagi H, Yamasaki Y, Yoo JY, Park B, Shin DM, Yoon HG, Yoon
JH. The extracellular signal-regulated kinase mitogen-activated protein
kinase/ribosomal S6 protein kinase 1 cascade phosphorylates cAMP response
element-binding protein to induce MUC5B gene expression via D-prostanoid receptor
signaling. J Biol Chem. 2011 Sep 30;286(39):34199-214. doi:
10.1074/jbc.M111.247684. PubMed PMID: 21832046; PubMed Central PMCID: PMC3190772.